Analyst firms · Leerink Partners · IPHA
Leerink Partners IPHA price target and rating history
Innate Pharma S.A. ADS (IPHA) · Health Care
Leerink Partners rates Innate Pharma S.A. ADS (IPHA) Market Perform with a $1 price target, as of its latest action on Nov 19, 2026. It has published 7 rating actions on IPHA since September 2021, including 4 upgrades and 2 downgrades.
- Current rating
- Market Perform
- Price target
- $1
- Median target, all firms
- Too few
- Actions on IPHA
- 7
Leerink Partners price target on IPHA
Every Leerink Partners rating on IPHA
- Nov 19, 2026
- Aug 11, 2026
- Sep 18, 2025
- Sep 17, 2021
- Sep 3, 2021
- Sep 3, 2021
- Sep 2, 2021
How other firms rate IPHA
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Leerink Partners | Market Perform | $1 | Nov 19, 2026 |
| BTIG | Buy | $8 | Mar 12, 2026 |
Questions about Leerink Partners and IPHA
- What is Leerink Partners's price target for IPHA?
- Leerink Partners's latest stated price target for Innate Pharma S.A. ADS (IPHA) is $1, from its action on Nov 19, 2026.
- What is Leerink Partners's rating on IPHA?
- Leerink Partners rates IPHA Market Perform, a neutral rating, as of Nov 19, 2026.
- When did Leerink Partners last change its view on IPHA?
- On Nov 19, 2026, Leerink Partners downgrades to Market Perform from Outperform, price target $1.
All Leerink Partners ratingsIPHA news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.